127 related articles for article (PubMed ID: 21867645)
41. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
42. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R; Kapur R
Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
[TBL] [Abstract][Full Text] [Related]
43. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
44. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract][Full Text] [Related]
45. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Nimmanapalli R; Bhalla K
Oncogene; 2002 Dec; 21(56):8584-90. PubMed ID: 12476305
[TBL] [Abstract][Full Text] [Related]
46. Oncogenes in myeloproliferative disorders.
Tefferi A; Gilliland DG
Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
[TBL] [Abstract][Full Text] [Related]
47. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
48. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
Gotlib J
Curr Hematol Malig Rep; 2015 Dec; 10(4):351-61. PubMed ID: 26404639
[TBL] [Abstract][Full Text] [Related]
49. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
50. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
51. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
52. Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies.
Naoe T
Curr Pharm Biotechnol; 2006 Oct; 7(5):331-7. PubMed ID: 17076649
[TBL] [Abstract][Full Text] [Related]
53. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.
Shallis RM; Wang R; Davidoff A; Ma X; Podoltsev NA; Zeidan AM
Blood Rev; 2020 Jul; 42():100706. PubMed ID: 32517877
[TBL] [Abstract][Full Text] [Related]
54. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
Yao S; Na L; Liangding H
Ann Hematol; 2024 Jun; ():. PubMed ID: 38888615
[TBL] [Abstract][Full Text] [Related]
55. The myeloproliferative neoplasms including the eosinophilia-related myeloproliferations associated with tyrosine kinase mutations: changes and issues in classification and diagnosis criteria.
Anastasi J
Semin Diagn Pathol; 2011 Nov; 28(4):304-13. PubMed ID: 22195408
[TBL] [Abstract][Full Text] [Related]
56. Kinases as drug discovery targets in hematologic malignancies.
Hannah AL
Curr Mol Med; 2005 Nov; 5(7):625-42. PubMed ID: 16305489
[TBL] [Abstract][Full Text] [Related]
57. Chromosomal translocations in cancer and their relevance for therapy.
Taki T; Taniwaki M
Curr Opin Oncol; 2006 Jan; 18(1):62-8. PubMed ID: 16357566
[TBL] [Abstract][Full Text] [Related]
58. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.
Havelange V; Demoulin JB
J Blood Med; 2013; 4():111-21. PubMed ID: 23976869
[TBL] [Abstract][Full Text] [Related]
59. The Role of MicroRNAs in Myeloproliferative Neoplasia.
Alizadeh S; Azizi SG; Soleimani M; Farshi Y; Kashani Khatib Z
Int J Hematol Oncol Stem Cell Res; 2016 Jul; 10(3):172-85. PubMed ID: 27489593
[TBL] [Abstract][Full Text] [Related]
60. Targeting non-malignant disorders with tyrosine kinase inhibitors.
Grimminger F; Schermuly RT; Ghofrani HA
Nat Rev Drug Discov; 2010 Dec; 9(12):956-70. PubMed ID: 21119733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
